Skoulidis et al. proposed a molecular classification of KRAS-mutated NSCLC into three distinct subgroups: the KL subtype (co-occurring Serine/Threonine Kinase 11 (STK11) and Kelch-like ECH-associated protein 1 (KEAP1) mutations), the KP subtype (associated with TP53 mutations), and the KC subtype (characterized by CDKN2A/B alterations and reduced TTF-1 expression) [112]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.